BrainsWay Ltd. (BWAY) Stock

BrainsWay Ltd. specializes in developing and marketing noninvasive neurostimulation treatments for various mental health disorders across the United States, Europe, Israel, and internationally. The company's core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), is designed to treat a wide range of conditions including major depressive disorders, anxious depression, obsessive-compulsive disorders, and smoking addiction.

Additionally, BrainsWay's Deep TMS platform extends its therapeutic reach to address bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. By offering these advanced treatments, BrainsWay provides innovative solutions to enhance the mental health and well-being of patients worldwide.

Founded in 2003 and headquartered in Jerusalem, Israel, BrainsWay primarily serves doctors, hospitals, and medical centers specializing in psychiatry. The company's mission is to advance mental health care through cutting-edge technology, making effective and noninvasive treatment options accessible to a broader patient population.